Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease - Takeaways - MDSpire

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

  • By

  • Naseel Moursy

  • Hibba Siraj

  • Zainab Nasir

  • Affaf Tanweer

  • Muhammad Raihan Sajid

  • April 22, 2026

  • 0 min

Share

  • 1

    Mass spectrometry (MS) profiling enhances multiple myeloma (MM) risk stratification beyond traditional static models.

  • 2

    MS-based biomarkers demonstrate independent prognostic significance, improving overall and progression-free survival predictions.

  • 3

    MS techniques achieve up to 1,000-fold higher sensitivity for minimal residual disease (MRD) detection compared to conventional methods.

  • 4

    MS allows for non-invasive, longitudinal MRD monitoring, identifying biochemical relapse significantly earlier than traditional assays.

  • 5

    Standardization of MS methodologies is essential for integrating MS-guided treatment adjustments into routine clinical practice.

Original Source(s)

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

  • by Naseel Moursy, Hibba Siraj, Zainab Nasir, Affaf Tanweer, Muhammad Raihan Sajid

  • April 22, 2026

Related Content

Evaluating Hypoalbuminemia as a Prognostic Indicator in Monoclonal Gammopathy of Undetermined Significance (MGUS) within Its Biological Framework

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review